

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ruddy et al.



Application No.: 08/852,495

Group Art Unit: 1644

Filed: May 7, 1997

Examiner: Vander Vegt, F.

For: POLYMORPHISMS IN THE
REGION OF THE HUMAN
HEMOCHROMATOSIS GENE

Attorney Docket No.: 8907-057-999

RECEIVED
MAR 17 2000
1600 MAIL ROOM

FEE TRANSMITTAL SHEET

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be \$0.

The claim amendment fee has been estimated as shown below:

(Col. 1)	(Col. 2)	(Col. 3)	SMALL ENTITY	OTHER THAN A SMALL ENTITY
CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NO PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	RATE
TOTAL 20 MINUS 28	= 0	×	9 \$	×
INDEP. 4 MINUS 6	= 0	×	39 \$	×
□ FIRST PRESENTATION OF MULTIPLE DEP. CLAIM			130 \$	+ 260 \$
			TOTAL \$	OR TOTAL \$
				0.00

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.
A copy of this sheet is enclosed.

Respectfully submitted,

Brian M. Poissant

Brian M. Poissant

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

28,462
(Reg. No.)

Date

March 13, 2000

Enclosure

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Ruddy *et al.*

Serial No.: 08/852,495

Filed: May 7, 1997

For: POLYMORPHISMS IN THE REGION OF
THE HUMAN HEMOCHROMATOSIS
GENE



Group Art Unit: 1644

Examiner: Vander Vegt, F.

Attorney Docket No.:
8907-057-999

AMENDMENT UNDER 37 C.F.R. § 1.116

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants have considered the final Office Action mailed December 22, 1999 in connection with the above-captioned application and respectfully request reconsideration of the claims in light of the amendments and remarks that follow.

AMENDMENTS

IN THE CLAIMS:

Please amend Claims 29-48 as follows:

29. (Amended) An isolated [, extrachromosomal] polynucleotide comprising at least 8 consecutive bases and up to about 100 consecutive bases of the sequence shown in SEQ ID NOS:1 or 2, or the complement thereof, wherein said isolated polynucleotide includes at least one polymorphic site shown in Table 1.

DO NOT
ENTER
R/
3/29/00